University of Pittsburgh Cancer Institute (UPCI)

Clinical Trials

Clinical TrialsClinical investigators in the CTP design and perform Phase I, Phase I/II, and Phase II studies of small molecule anticancer agents, either alone or in combination with other drugs.

Selected Publications

  • Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). Patients with mCRC refractory to first-line fluoropyrimidine/oxaliplatin regimens and not previously treated with I+C were treated every 2 weeks with I+C. No efficacy of this combination was demonstrated at the dose and schedule tested (Carneiro BA et. al. Clin Colorectal Cancer. 11:53-9, 2012).
  • The addition of bevacizumab to paclitaxel improved progression-free survival of patients with metastatic breast cancer. In a phase II clinical trial, CTP investigators examined the efficacy and safety of adding gemcitabine to paclitaxel/bevacizumab. Although this triple drug regimen generally was well tolerated, it did not improve the overall response rate (Brufsky A et. al. Clin Breast Cancer 11:211-20, 2011).
  • MTTDP participated in a phase III clinical study that compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. The combination of bevacizumab with commonly used chemotherapies improved progression-free survival in the second-line treatment of patients with HER2-negative metastatic breast cancer, with a safety profile comparable with that in prior phase III studies (Brufsky AM et. al. J Clin Oncol 29:4286-93, 2011).


Appleman, Leonard, MD, PhD
Mountz, James, MD, PhD
Bahary, Nathan, MD, PhD
Ragni, Margaret, MD, MPH
Jakacki, Regina, MD
Pediatrics (CHP)
Redner, Robert, MD
Maranchie, Jodi, MD, FACS
Stoller, Ronald, MD